PHILADELPHIA--(BUSINESS WIRE)--iCeutica Inc., today announced that its wholly owned subsidiary has been awarded a key patent for its SoluMatrix Fine Particle Technology™ platform by the U.S. Patent and Trademark Office (USPTO). The patent, No. 8,808,751, covers the company’s dry milling method for producing submicron-sized particles that are 10 to 200 times smaller than conventional drug particles.
“This patent further strengthens our intellectual property around the SoluMatrix™ technology, which serves as the foundation of our business model of creating enhanced branded medications with improved pharmacokinetics and therapeutic effect,” said Matt Callahan, CEO of iCeutica. “SoluMatrix™ technology has already been incorporated into two FDA approved drugs in three indications and has fueled 15 of iCeutica’s additional pipeline candidate programs. This patent grant by the USPTO is an important milestone in our goal of protecting the commercial potential of products utilizing our proprietary technology platform.”
Help employers find you! Check out all the jobs and post your resume.
